ProCE Banner Activity

CME

A Case-Based Focus on Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas

Multimedia
Watch this webcast from a live symposium where experts discuss targeted therapies and clinical considerations in the management of neurofibromatosis type 1 and inoperable plexiform neurofibromas.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: July 08, 2022

Expiration: July 07, 2023

No longer available for credit.

Share

Faculty

Miriam Bornhorst

Miriam Bornhorst, MD

Clinical Director 
Gilbert Neurofibromatosis Clinic
Medical Director 
Cancer Genetics Clinic
Attending Neuro-oncologist
Department of Neurology and Oncology
Center for Genetics Medicine Research
Children's National Hospital
Assistant Professor of Pediatrics
George Washington University
Washington, D.C.

Carlos Romo

Carlos Romo, MD

Assistant Professor of Neurology, Oncology and Medicine Director of Clinical Research
The Neurofibromatosis Therapeutic Acceleration Program
Department of Neurology
Johns Hopkins University School of Medicine
Baltimore, Maryland

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Alexion Pharmaceuticals

Target Audience

This activity is intended for pediatric oncologists and other healthcare professionals who care for pediatric patients with neurofibromatosis type 1 who have inoperable plexiform neurofibromas.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Evaluate the mechanisms of action of therapeutic approaches targeted to cell signaling pathways affected in NF-1
  • Describe to patients’ parents and caregivers the currently approved and emerging therapeutic strategies for the treatment of NF-1 and inoperable plexiform neurofibromas
  • Plan the use of novel targeted agents for patients with neurofibromatosis type 1 who have inoperable plexiform neurofibromas, taking into consideration available safety, efficacy, and quality of life data
  • Manage adverse events associated with approved targeted systemic treatments

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Miriam Bornhorst, MD

Clinical Director 
Gilbert Neurofibromatosis Clinic
Medical Director 
Cancer Genetics Clinic
Attending Neuro-oncologist
Department of Neurology and Oncology
Center for Genetics Medicine Research
Children's National Hospital
Assistant Professor of Pediatrics
George Washington University
Washington, D.C.

Miriam Bornhorst, MD, has no relevant financial relationships to disclose.

Carlos Romo, MD

Assistant Professor of Neurology, Oncology and Medicine Director of Clinical Research
The Neurofibromatosis Therapeutic Acceleration Program
Department of Neurology
Johns Hopkins University School of Medicine
Baltimore, Maryland

Carlos Romo, MD, has no relevant financial relationships to disclose.

Staff Disclosure

Staff

Marie N. Becker, PhD

Scientific Director

Marie Becker, PhD, has no relevant conflicts of interest to report.

Francesca Biasucci,

Francesca Biasucci has no relevant conflicts of interest to report.

Kelly Brandt, PharmD

Kelly G. Brandt, PharmD, BCOP, BCPS, has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 08, 2022, through July 07, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge and competence of pediatric medical oncologists and other healthcare professionals who use novel targeted therapies in the treatment of pediatric patients with NF-1 plexiform neurofibromas.